Assess Ovarian Cancer Risk Prior to Surgery. 
Introducing OVA1®plus

What is OVA1®plus?

For women with adnexal mass, OVA1®plus is a reflex process which first performs OVA1® and then performs OVERA® if the OVA1® result is in the intermediate range.

The combination of OVA1® and OVERA® helps you further stratify your patients risk of malignancy.

Low Risk is <4.4 (Postmenopausal) and <5.0 (Premenopausal) Intermediate Risk is 4.4-6.0 (Postmenopausal) and 5.0-7.0 (Premenopausal) Markedly Elevated Risk is >6.0 (Postmenopausal) and >7.0 (Premenopausal)

What are the Benefits of OVA1®plus?

The combination of OVA1® and OVERA® helps you further stratify your patients risk of malignancy.

Reduces the falsely elevated rate in the intermediate range by OVER 50%

Maintaining the high rate of detection for risk of malignancy 96% SENSITIVITY¹ (with clinical assessment) especially in early stage disease and all ethnicities

Provides confidence in negative results with a 98% NEGATIVE¹ predictive value.

OVA1® is an FDA cleared multivariate index assay (MIA) that combines the results of five biomarkers and a proprietary algorithm to provide a malignancy risk index.

OVA1® is an FDA cleared second generation multivariate index assay (MIA) that combines the results of five biomarkers and a proprietary algorithm to provide a malignancy risk index.

OVERA® is performed when the OVA1® result is in the intermediate range.

OVERA® is an FDA cleared second generation multivariate index assay (MIA) that combines the results of five biomarkers and a proprietary algorithm to provide a malignancy risk index.

OVERA® is performed when the OVA1® result is in the intermediate range.

98% Negative Predictive Value
96% Sensitivity (with clinical assessment)
Guideline support from ACOG, SGO & NCCN

OVERA® is performed when the OVA1® result is in the intermediate range.
69% Specificity, 91% Sensitivity²
Performing OVERA® in this range further stratifies risk and reduces the falsely elevated rate

---


OVA1® should be used in women >18yrs that have a pelvic mass to assess ovarian cancer risk prior to surgical treatment planning. It should be used in combination with clinical assessment and is not a screening test.

844.277.4721 ASpiRAlab.com

© 2018 Vermillion. All rights reserved. The ASPIRA LABS and OVA1® logos are registered trademarks of Vermillion in the U.S. and other countries. Vermillion reserves the right to change this document at any time without notice and disclaims liability for editorial, pictorial or typographical errors.